Qualia Life
98/100
This product looks safe
- Niacin: 125mg is 3.6× the Tolerable Upper Intake Level (35mg)
- Folate: 303mg is 303.0× the Tolerable Upper Intake Level (1.0mg)
- 50% of ingredients have research evidence
D
Label Compliance Grade
Product Label
Have a supplement label? Find it here.
Upload a photo of any supplement label to search our database of 92,312 products.
Safety Alerts
⚠️ Niacin: 125mg is 3.6× the Tolerable Upper Intake Level (35mg)
⚠️ Folate: 303mg is 303.0× the Tolerable Upper Intake Level (1.0mg)
Label Data
8 Vegetarian Capsule(s)
Serving Size
20
Servings
Other Combinations
Product Type
50%
Evidence Coverage
Supplement Facts — Evidence Check
50 mcg
(42% DV)
✅ Within RDA (0.4× RDA of 0.12 mg)
📚 273 studies (Tier A: 9, B: 175)
25 mg
(2085% DV)
📊 20.8× RDA — above typical dose
📚 76 studies (Tier A: 0, B: 33)
2 mg
(154% DV)
✅ 1.5× RDA — within safe limits
📚 12 studies (Tier A: 0, B: 1)
125 mg
(781% DV)
⚠️ Exceeds Tolerable Upper Intake Level by 3.6× (UL: 35 mg)
📚 193 studies (Tier A: 5, B: 63)
1.3 mg
(76% DV)
✅ Within RDA (1.0× RDA of 1.3 mg)
📚 113 studies (Tier A: 3, B: 35)
303 mcg DFE
(76% DV)
⚠️ Exceeds Tolerable Upper Intake Level by 303.0× (UL: 1.0 mg)
📚 225 studies (Tier A: 10, B: 105)
200 mcg
(8330% DV)
📊 83.3× RDA — above typical dose
📚 138 studies (Tier A: 1, B: 44)
30 mcg
(100% DV)
✅ Within RDA (1.0× RDA of 0.03 mg)
📚 26 studies (Tier A: 0, B: 11)
5 mg
(100% DV)
✅ Within RDA (1.0× RDA of 5 mg)
📚 1 studies — no high-quality reviews
48 mg
(11% DV)
📊 Market median: 4002.0mg (1 products)
📚 20 studies (Tier A: 0, B: 2)
1000 mg
📊 Market median: 5.0mg (298 products)
📚 701 studies (Tier A: 5, B: 123)
📊 Market median: 4002.0mg (1 products)
📚 20 studies (Tier A: 0, B: 2)
Glycine
344 mg
Rosmarinus officinalis leaf extract
300 mg
Cocoa seed extract
300 mg
Cinnulin PF Cinnamomum burmannii bark extract
250 mg
250 mg
📊 Market median: 500.0mg (861 products)
📚 60 studies (Tier A: 4, B: 13)
BioVin French Red Grapes extract
200 mg
200 mg
📊 Market median: 550.0mg (217 products)
📚 29 studies (Tier A: 0, B: 5)
elevATP
150 mg
125 mg
📊 Market median: 496.0mg (192 products)
📚 20 studies — no high-quality reviews
📊 Market median: 450.0mg (502 products)
📚 28 studies (Tier A: 0, B: 8)
Gynostemma pentaphyllum whole herb extract
100 mg
Sirtmax Kaempferia parviflora root extract
100 mg
100 mg
📊 Market median: 4002.0mg (1 products)
📚 20 studies (Tier A: 0, B: 2)
N-Acetyl-L-Cysteine
100 mg
100 mg
📊 Market median: 500.0mg (70 products)
65 mg
📊 Market median: 100.0mg (283 products)
📚 142 studies (Tier A: 1, B: 64)
Sophorae japonica L. flower extract
50 mg
Citrus sinensis L. fruit extract
50 mg
Strawberry seed extract
40 mg
Citrus grandis fruit extract
20 mg
📊 Market median: 4002.0mg (1 products)
📚 20 studies (Tier A: 0, B: 2)
Ceratonia siliqua pod extract
5 mg
Other Ingredients
Hypromellose
organic Rice concentrate
organic Rice extract Blend
Silicon Dioxide
Calcium Carbonate
Label Claims — Verification
❓
Structure/Function
All Other (100% of products)
Structure/Function (84% of products)
Nutrient (73% of products)
Target Groups
Adult (18 - 50 Years)
Product Information
🧪 Formulation Notes
Optimized aging Energy Sleep Cognition
Cinnulin PF BioVin Advanced with Red Wine extract, with 5% Reservatrol elevATP Strength, Power, Performance Sensoril
Manufactured in a cGMP compliant facility
Additional Information
28 day supply
Product Details
Research Evidence
332
Research Sources
59
Avg Quality Score
220
Meta Analysis
56
Systematic Review
30
Rct
16
Clinical Trial
3
Guideline
3
Regulatory Source
1
Narrative Review
1
Other
1
Openfda Safety
A
Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism
A
Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
A
Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
A
Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
A
Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair
A
Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
A
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
A
Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
Compare Similar Products
Vitamin D Synergy with Vitamin K1
Designs for Health
100
Vitamin D Synergy with Vitamin K1
Designs for Health
100
Natural Vitamin K2 45 mcg
Doctor's Best
100
K 100 mcg
Thompson
100
Vitamin K2 300 mcg MK-7
Innerzyme
100